RecruitingNAINTERVENTIONAL

PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

This study is about improving how we diagnose and monitor multiple myeloma, a cancer that mainly affects the bones. Currently, doctors use blood tests and standard scans like PET/CT and MRI to understand how much of the body is affected. This trial wants to see if a newer, more advanced scan, called a PET/MR, using a special tracer called [68Ga]Ga-PentixaFor, can give even clearer and more exact information. The aim is to find out if this new scan can help doctors see the cancer better, guide treatment decisions, and reduce the need for multiple different scans for patients.

At a glance

Status

Recruiting

Phase

Sponsor

University Health Network, Toronto

Enrolment target

Start

22 Apr 2025

Estimated completion

04 Mar 2028

Multiple Myeloma

What is this study about?

Multiple myeloma is a type of cancer that mostly affects the bones. When someone is diagnosed, their doctor usually does blood tests and special scans (like PET/CT and sometimes MRI) to see how many bones or other parts of the body are affected. While these current scans are quite good, scientists are always looking for ways to make them even better.

This study aims to find out if a new combined PET/MR scan, using a special substance called [68Ga]Ga-PentixaFor, can provide more accurate and precise information. We want to see if this new scan can help doctors understand the disease more clearly, right from the start and as it is being treated.

Ultimately, if this new scanning method proves to be better, it could help doctors make more informed treatment choices for people with multiple myeloma. This could lead to better ways to keep track of the disease and potentially reduce how many different scans a patient needs.

Key takeaways

This study explores a new, advanced PET/MR scan for multiple myeloma.
It aims to improve how doctors see and understand the cancer in the bones.
A special tracer called [68Ga]Ga-PentixaFor is used in the new scan.
The goal is more accurate diagnosis and better treatment decisions.
It might reduce the need for multiple different scans.
It's comparing a new method against standard care.

Who may be eligible?

To join this study, you need to be over 18 years old and have a diagnosis of multiple myeloma that meets certain medical guidelines. You also shouldn't have had any treatment beyond an initial course for your multiple myeloma.

You cannot take part if you have certain medical conditions that might prevent you from having an MRI or a standard PET/CT scan. This includes if you are pregnant or breastfeeding, or if you cannot lie still for about 30 minutes for the scans. You also can't participate if you are allergic to the special substance used in the new scan ([68Ga]Ga-PentixaFor), or if you can't give your clear permission to be part of the study.

Also, if you have another type of blood cancer (like another lymphoma or leukaemia) at the same time, this study wouldn't be suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of multiple myeloma?
Have you started initial treatment for your multiple myeloma but gone no further?
Can you lie still for around 30 minutes for a scan?
Are you not pregnant or breastfeeding?
Are you not allergic to the special substance used in the new scan?

Answer every question to see your result.

What does participation involve?

The detailed involvement isn't fully described, but generally, if you participate in this study, you would likely undergo the new PET/MR scan using the special substance [68Ga]Ga-PentixaFor. This special scan would then be compared to the results from your usual standard scans (like PET/CT and MRI). The study aims to see if this new scan provides better information for initial diagnosis, ongoing monitoring, and helping doctors decide on your treatment. You would be compared against the standard care received by others. The specific number of visits, assessments, and the total duration would be explained in full detail by the study team if you express interest.

Potential risks and benefits

Participating in this study might offer the benefit of receiving a very advanced and potentially more detailed scan of your multiple myeloma, which could improve understanding of your disease. However, there's always a small risk with any medical procedure or scan, including potential allergic reactions to the special substance used in the scan, or discomfort from lying still for the scan. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

University Health Network
Verified postcode
Toronto, Canada· Recruiting

Common questions

What is multiple myeloma?

Multiple myeloma is a type of cancer that starts in the bone marrow, the soft tissue inside your bones that makes blood cells. It mainly affects the bones.

What is a PET/MR scan?

A PET/MR scan is a special imaging test that combines two different types of scans (PET and MRI) into one machine. This can give doctors very detailed pictures of what's happening inside your body.

What is [68Ga]Ga-PentixaFor?

[68Ga]Ga-PentixaFor is a special 'tracer' substance that is put into your body for the PET/MR scan. It helps certain parts of the body, like cancer cells, show up more clearly on the scan.

Why is this study important?

This study is important because it is trying to find a better and more accurate way to see and understand multiple myeloma. This could help doctors make better decisions about treatment for patients.

Will I still get my usual care if I join this study?

Yes, joining this study will not stop you from receiving your usual medical care and treatment for multiple myeloma. The study is about seeing if a new scan can add to or improve current methods.

How to find out more

Patrick Veit-Haibach, MD

patrick.veit-haibach@uhn.ca 416-340-4800 Ext. 6085 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.